How does mismatch repair deficiency affect Melanoma treatment

Mismatch Repair Deficiency and Melanoma Treatment

Thank you for this important question. Let me explain how mismatch repair (MMR) deficiency relates to melanoma treatment based on current medical evidence.

What is Mismatch Repair Deficiency?

Mismatch repair is a cellular "proofreading" system that fixes errors when DNA is copied. When this system doesn't work properly (MMR deficiency), mutations accumulate in cancer cells. This creates what's called "microsatellite instability" (MSI) or a "high tumor mutational burden" (TMB) — essentially, the cancer cells have many genetic errors.

How This Affects Melanoma Treatment

The Clinical Reasoning:

Doctors have discovered that melanomas with MMR deficiency or high tumor mutational burden tend to respond better to immunotherapy — treatments that help your immune system recognize and attack cancer cells. Here's why:

• The accumulated mutations in MMR-deficient tumors create unique "markers" (called neoantigens) that make cancer cells look foreign to your immune system
• These markers help immune checkpoint inhibitors (like pembrolizumab and nivolumab) work more effectively by allowing T cells to better recognize and kill the cancer cells
• This is why testing for MMR status and tumor mutational burden has become increasingly important in melanoma care

What This Means for Treatment Decisions

According to the NCCN Guidelines for Patients: Melanoma (2025), immunotherapy options for melanoma include:

• Pembrolizumab (Keytruda) — a checkpoint inhibitor
• Nivolumab (Opdivo) — another checkpoint inhibitor
• Combination approaches with ipilimumab for certain situations

Patients with MMR deficiency may be candidates for these immunotherapies, and some may also be eligible for clinical trials testing newer approaches specifically designed for MMR-deficient cancers.

Questions to Ask Your Oncology Team

1. Has my melanoma been tested for mismatch repair deficiency or tumor mutational burden? If not, should it be?
2. If I have MMR deficiency, how does this change my treatment recommendations?
3. Am I a candidate for immunotherapy based on my MMR status?
4. Are there clinical trials available for MMR-deficient melanoma that I should consider?
5. How will my doctor monitor my response to treatment if I receive immunotherapy?

Important Boundary

While MMR deficiency is an important biomarker that oncologists consider when planning melanoma treatment, your specific treatment plan depends on your complete clinical picture — including your melanoma stage, other genetic mutations (like BRAF status), your overall health, and previous treatments. Your oncologist will determine the most appropriate approach for YOUR individual case based on all available information.

The NCCN Guidelines emphasize that treatment decisions should be made collaboratively between you and your care team, considering both standard approaches and clinical trial options that may be available to you.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.